RxDoctor Payments Data

David Sullivan, MD

Hematology & Oncology · Memphis, TNNPI 1851399638

Payments from drug & device makers

$12,954in general payments, 2019–2025

Across 732 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$961
  • Pfizer$893
  • E.r. Squibb & Sons, L.L.C.$892
  • Merck$845
  • Gilead$763
  • Johnson & Johnson$725
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,47796%
  • Education$4774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis58$961
Pfizer55$893
E.r. Squibb & Sons, L.L.C.74$892
Merck42$845
Gilead(2 entities)39$763
Johnson & Johnson(2 entities)42$725
Bristol Myers Squibb37$694
AstraZeneca(2 entities)38$666
Amgen25$525
Lilly USA, LLC27$522
AbbVie21$420
Daiichi Sankyo Inc.21$389
GSK17$332
Takeda Pharmaceuticals U.S.A., Inc.13$308
Astellas Pharma US Inc12$299
Incyte Corporation16$291
Seagen Inc.18$288
Genentech USA, Inc.16$260
Eisai Inc.13$245
Boehringer Ingelheim14$196
Bayer11$190
Rigel Pharmaceuticals, Inc.10$182
Exelixis Inc.7$131
Tempus AI, Inc6$110
EMD Serono, Inc.5$106
Mirati Therapeutics, Inc.5$89
Tesaro, Inc.3$83
Servier Pharmaceuticals LLC4$82
Puma Biotechnology, Inc.5$82
Regeneron Healthcare Solutions, Inc.4$80
Pharmacyclics LLC, An Abbvie Company4$79
Sobi, Inc4$72
AVEO Pharmaceuticals, Inc.4$71
AMAG Pharmaceuticals, Inc.5$69
Beigene USA, Inc.3$68
Coherus Oncology, Inc.4$64
Genmab U.S., Inc.3$63
Sumitomo Pharma America, Inc.2$58
Sanofi3$52
Blueprint Medicines Corporation3$51
Stemline Therapeutics Inc.2$44
Geron Corporation2$43
Kyowa Kirin, Inc.3$42
Jazz Pharmaceuticals Inc.2$37
Beone Medicines USA, Inc.2$37
Taiho Oncology, Inc.2$36
Karyopharm Therapeutics Inc.2$34
Morphosys, US Inc.2$30
Teva Pharmaceuticals USA, Inc.2$28
Secura Bio, Inc.2$23
Sanofi US Services Inc.1$22
Legend Biotech USA Inc.1$22
Octapharma USA, Inc.1$21
Tolmar Pharmaceuticals, Inc.1$21
Biocompatibles, Inc.1$20
ADC Therapeutics America, Inc.1$18
Acrotech Biopharma Inc.1$18
Foundation Medicine, Inc.1$18
Tersera Therapeutics LLC1$17
Apellis Pharmaceuticals, Inc.1$16

How this compares

$12,954 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$95,991
Medicare patients
343
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide30$514,964
IbrancePalbociclib18$271,462
ImbruvicaIbrutinib11$169,012
DopteletAvatrombopag Maleate14$102,343
EliquisApixaban96$76,924
XareltoRivaroxaban85$57,683
Imatinib Mesylate25$22,145
Oxycodone Hcl43$1,695
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$1,535
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$1,333
Potassium Chloride63$1,179
Anastrozole115$731
Megestrol Acetate19$612
Verapamil SrVerapamil Hcl12$568
Albuterol Sulfate HfaAlbuterol Sulfate14$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$893$348,386114 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$79$169,01211 claims
Johnson & JohnsonXarelto$725$57,68385 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$28$8123 claims
Lilly USA, LLCOlanzapine$522$2912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →